James Gita Hakim

Q: What Schools Are Affiliated With James Gita Hakim

James Gita Hakim is affiliated with the following schools: Makerere University, University of Newcastle , University of Zimbabwe, University of California, San Francisco, University of Nairobi

James Gita Hakim's AcademicInfluence.com Rankings

James Gita Hakim

Philosophy

#11871

World Rank

#16414

Historical Rank

Logic

#8679

World Rank

#10885

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is James Gita Hakim Influential?

(Suggest an Edit or Addition)

According to Wikipedia, James Gita Hakim , was a South Sudanese and Ugandan, internist, clinical epidemiologist, cardiologist, researcher, university faculty and academic mentor. At the time of his death, he was Professor of Medicine and Former Chair of Internal Medicine at the University of Zimbabwe College of Health Sciences.

(See a Problem?)

James Gita Hakim's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prevention of HIV-1 infection with early antiretroviral therapy. (2011) (2213)
Antiretroviral Therapy for the Prevention of HIV-1 Transmission. (2016) (1154)
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. (2011) (557)
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. (2014) (445)
Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients (2000) (223)
Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. (2010) (208)
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. (2014) (206)
Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission (2018) (193)
Assessment of second-line antiretroviral regimens for HIV therapy in Africa. (2014) (183)
One Month of Rifapentine plus Isoniazid to Prevent HIV‐Related Tuberculosis (2019) (182)
The magnitude of loss to follow-up of HIV-exposed infants along the prevention of mother-to-child HIV transmission continuum of care: a systematic review and meta-analysis (2013) (167)
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. (2008) (159)
Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial (2012) (148)
Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients (2000) (145)
Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort (2010) (140)
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. (2021) (138)
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa (2017) (136)
Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa (2006) (130)
Antiretroviral therapies in women after single-dose nevirapine exposure. (2010) (130)
Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings (2012) (125)
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. (2011) (116)
Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. (1998) (113)
Prevalence, Incidence and Predictors of Severe Anaemia with Zidovudine-Containing Regimens in African Adults with HIV Infection within the Dart Trial (2005) (104)
Impact of Human Immunodeficiency Virus Infection on Cardiovascular Disease in Africa (2005) (96)
Characterization of HIV–HBV coinfection in a multinational HIV-infected cohort (2013) (93)
Three lessons for the COVID-19 response from pandemic HIV (2020) (87)
Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe (2012) (75)
Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial. (2015) (75)
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). (2013) (73)
Tobacco use among people living with HIV: analysis of data from Demographic and Health Surveys from 28 low-income and middle-income countries (2017) (70)
Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. (2010) (69)
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. (2010) (64)
Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome (2002) (64)
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial (2016) (63)
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial (2017) (60)
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial (2017) (60)
Myocardial dysfunction in human immunodeficiency virus infection: an echocardiographic study of 157 patients in hospital in Zimbabwe. (1996) (59)
Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. (2012) (56)
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV. (2021) (53)
25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings. (2014) (51)
Psychosocial Predictors of Non-Adherence and Treatment Failure in a Large Scale Multi-National Trial of Antiretroviral Therapy for HIV: Data from the ACTG A5175/PEARLS Trial (2014) (50)
Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults. (2016) (50)
Chronic cough in primary health care attendees, Harare, Zimbabwe: diagnosis and impact of HIV infection. (2005) (49)
Nursing and community rates of Mycobacterium tuberculosis infection among students in Harare, Zimbabwe. (2007) (47)
Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation (2016) (46)
High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy (2013) (44)
Estimating Glomerular Filtration Rate in HIV-Infected Adults in Africa: Comparison of Cockcroft–Gault and Modification of Diet in Renal Disease Formulae (2008) (41)
A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings (2011) (41)
Cardiac Disease in Adolescents With Delayed Diagnosis of Vertically Acquired HIV Infection (2012) (40)
NeuroAIDS in Africa (2010) (39)
Glomerular Dysfunction and Associated Risk Factors over 4–5 Years following Antiretroviral Therapy Initiation in Africa (2011) (37)
Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe (2012) (35)
Sex-Associated Differences in Pre-Antiretroviral Therapy Plasma HIV-1 RNA in Diverse Areas of the World Vary by CD4+ T-Cell Count (2011) (33)
Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: a 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis. (2013) (33)
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. (2020) (31)
Metabolic syndrome disorders in urban black Zimbabweans with type 2 Diabetes mellitus. (2004) (30)
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial (2018) (30)
Does Trimethoprim-Sulfamethoxazole Prophylaxis for HIV Induce Bacterial Resistance to Other Antibiotic Classes?: Results of a Systematic Review (2011) (30)
The Lablite project: A cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe (2014) (30)
International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271 (2016) (28)
Cardiac disease distribution among patients referred for echocardiography in Harare, Zimbabwe. (1998) (28)
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial (2018) (27)
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial (2018) (27)
Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir in the Absence of Real-Time Viral Load Monitoring (2010) (26)
Rapid emergence of resistance to penicillin and trimethoprim-sulphamethoxazole in invasive Streptococcus pneumoniae in Zimbabwe. (2003) (24)
Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial (2018) (24)
A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings (2015) (24)
Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial (2018) (23)
Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy. (2013) (23)
C-Reactive Protein (CRP), Interferon Gamma-Inducible Protein 10 (IP-10), and Lipopolysaccharide (LPS) Are Associated with Risk of Tuberculosis after Initiation of Antiretroviral Therapy in Resource-Limited Settings (2015) (23)
A Single CD4 Test with 250 Cells/Mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria (2013) (22)
Virologic outcomes in early antiretroviral treatment: HPTN 052 (2017) (22)
The impact of first year adherence to antiretroviral therapy on long‐term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe (2012) (22)
Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial (2018) (21)
Feasibility and sustainability of an interactive team-based learning method for medical education during a severe faculty shortage in Zimbabwe (2014) (21)
Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe’s national antiretroviral therapy programme between 2012 and 2015 (2019) (20)
Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case–Cohort Study (2015) (20)
Adult Hematology and Clinical Chemistry Laboratory Reference Ranges in a Zimbabwean Population (2016) (19)
Cryptococcus myelitis: atypical presentation of a common infection. (2001) (19)
Cost Effectiveness Analysis of Routine Laboratory or Clinically Driven Strategies for Monitoring Anti-Retroviral Therapy in Uganda and Zimbabwe (DART Trial) (2009) (18)
Implementation of antiretroviral therapy for life in pregnant/breastfeeding HIV+ women (Option B+) alongside rollout and changing guidelines for ART initiation in rural Zimbabwe: the Lablite Project experience (2017) (18)
Comparison of HBV-active HAART regimens in an HIV–HBV multinational cohort: outcomes through 144 weeks (2015) (18)
Clinical characteristics and outcomes of patients with stroke admitted to three tertiary hospitals in Zimbabwe: A retrospective one-year study (2017) (18)
Second assessment of NeuroAIDS in Africa (2008) (17)
Assessment of neurocognitive deficits in people living with HIV in Sub Saharan Africa: A systematic review (2019) (17)
The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models (2015) (17)
Phylogenetic methods inconsistently predict direction of HIV transmission among heterosexual pairs in the HPTN052 cohort. (2019) (16)
Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants (2017) (15)
Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study (2014) (15)
Neurocognitive impairment in treatment-experienced adults living with HIV attending primary care clinics in Zimbabwe (2020) (15)
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial (2020) (14)
Hepatitis C virus and HIV antibodies in patients with hepatocellular carcinoma in Zimbabwe: a pilot study. (1997) (14)
Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda (2015) (14)
Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial (2016) (14)
Enhanced infection prophylaxis reduces mortality in severely immunosuppressed HIV-infected adults and older children initiating antiretroviral therapy in Kenya, Malawi, Uganda and Zimbabwe: the REALITY trial (2016) (14)
Impact of routine laboratory monitoring over 5 years after antiretroviral therapy (ART)initiation on clinical disease progression of HIV-infected African adults: the DART Trial finalresults (2009) (13)
Continued Elevation of Interleukin-18 and Interferon-γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort (2016) (13)
Hepatitis B serological markers and plasma DNA concentrations (2017) (13)
HIV prevention in southern Africa: why we must reassess our strategies? (2011) (13)
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing (2021) (12)
Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial. (2019) (12)
Acute myocardial infarction in Zimbabwe: the changing scene of coronary artery disease. (1995) (12)
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing (2021) (12)
Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys. (2017) (11)
Emergence and evolution of drug resistance in the absence of viral load monitoring during 48 weeks of Combivir/Tenofovir within the DART Trial. (2007) (11)
Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline study (2016) (11)
Impact of NRTI Cross-Resistance on Second-line PI + NRTI Therapy Outcomes in Africa (2015) (11)
HIV treatment and care systems: the way forward (2012) (10)
Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa (2010) (10)
Improving psychiatric education and research capacity in Zimbabwe (2014) (10)
Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial (2015) (9)
Clinical Differences between Younger and Older Adults with HIV/AIDS Starting Antiretroviral Therapy in Uganda and Zimbabwe: A Secondary Analysis of the DART Trial (2013) (9)
HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052 (2017) (9)
HIV-1 and TB Co-infection in Multinational Resource Limited Settings: Increased neurological dysfunction. (2018) (9)
Patient-mix, programmatic characteristics, retention and predictors of attrition among patients starting antiretroviral therapy (ART) before and after the implementation of HIV “Treat All” in Zimbabwe (2020) (9)
Echocardiographic assessment of left ventricular hypertrophy diastolic dysfunction and pericardial disease in patients on maintenance haemodialysis. (1996) (8)
Evaluation of Phylogenetic Methods for Inferring the Direction of Human Immunodeficiency Virus (HIV) Transmission: HIV Prevention Trials Network (HPTN) 052 (2020) (8)
Glomerular dysfunction and associated risk factors through four years following initiation of ART in adults with HIV Infection in Africa in the DART trial (2008) (8)
Evaluation of phylogenetic methods for inferring the direction of HIV transmission: HPTN 052. (2020) (8)
Hematological and biochemical laboratory reference intervals for Zimbabwean adolescents. (2015) (8)
Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses From the EARNEST Trial (2016) (8)
Renal and Metabolic Toxicities Following Initiation of HIV-1 Treatment Regimen in a Diverse, Multinational Setting: A Focused Safety Analysis of ACTG PEARLS (A5175) (2014) (8)
A structured treatment interruption (STI) strategy of 12 week cycles on and off DART is clinically inferior to continuous treatment in patients with low CD4 counts before ART: a randomization within the DART trial. (2006) (8)
Outcomes among HIV-1 Infected Individuals First Starting Antiretroviral Therapy with Concurrent Active TB or Other AIDS-Defining Disease (2013) (7)
Distal Sensory Peripheral Neuropathy in Human Immunodeficiency Virus Type 1-Positive Individuals Before and After Antiretroviral Therapy Initiation in Diverse Resource-Limited Settings. (2019) (7)
“Well, not me, but other women do not register because...”- Barriers to seeking antenatal care in the context of prevention of mother-to-child transmission of HIV among Zimbabwean women: a mixed-methods study (2018) (7)
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial (2018) (7)
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial (2018) (7)
Patient-level benefits associated with decentralization of antiretroviral therapy services to primary health facilities in Malawi and Uganda. (2018) (6)
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. (2022) (6)
Lablite: baseline mapping survey of decentralised ART service provision in Malawi, Uganda and Zimbabwe. (2012) (6)
Differential human immunodeficiency virus risk factors among female general nurses, nurse midwives and office workers/teachers in Zambia. (1996) (6)
HIV Associated Neurocognitive Impairment in Diverse Resource Limited Settings. (2018) (6)
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. (2020) (6)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
The SARS-CoV-2 epidemic in Zimbabwe: Quo vadis? (2020) (5)
Validation of the GenoType® MTBDRplus Ver 2.0 assay for detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis complex isolates at UZCHS-CTRC TB research laboratory (2019) (5)
Least among equals. (2012) (5)
Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy (2016) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
Clinical characteristics and outcomes of patients with stroke admitted in tertiary hospitals in Zimbabwe : A retrospective one-year study (2017) (4)
Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
Comparative skin testing with PPD tuberculin, Mycobacterium avium and M. scrofulaceum sensitin in schoolchildren in Saudi Arabia. (1994) (4)
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Epidemic in Zimbabwe: Quo Vadis? (2020) (4)
Eff ects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection : results from the phase 3 HPTN 052 randomised controlled trial (2014) (4)
Peripartum cardiomyopathy among cardiovascular patients referred for echocardiography at Parirenyatwa Teaching Hospital, Harare, Zimbabwe (2017) (4)
Rheumatic fever and rheumatic heart disease among children presenting to two referral hospitals in Harare, Zimbabwe. (2015) (4)
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial (2022) (4)
The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data (2017) (4)
Endomyocardial fibrosis in Zimbabwe--how rare is it? A report of two cases. (1996) (4)
Herpes Simplex Virus Type 2 Acquisition Among HIV-1–Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study (2017) (4)
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda (2014) (3)
Clinical trials in the use of antiretroviral therapy in developing countries: results and challenges (2007) (3)
Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. (2017) (3)
Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052 (2017) (3)
Facilitators and barriers to cotrimoxazole and nevirapine prophylaxis among HIV exposed babies: a qualitative study from Harare, Zimbabwe (2012) (3)
Empiric Tuberculosis Therapy versus Isoniazid in Advanced HIV-infected Adult Outpatients Initiating Antiretroviral Therapy : a Multi-Country Randomized Controlled Trial (2016) (2)
12-week raltegravir-intensified quadruple therapy versus triple first-line ART reduces viral load more rapidly but does not reduce mortality in severely immunosuppressed African HIV-infected adults and older children: the REALITY trial (2016) (2)
Manuscript title: Facilitators and barriers to cotrimoxazole prophylaxis among HIV exposed babies: a qualitative study from Harare, Zimbabwe (2015) (2)
Second-line treatment in sub-Saharan Africa: week 144 follow-up of the EARNEST trial (2015) (2)
Targeted needs analysis for people who have survived stroke and their caregivers in local communities in Zimbabwe (2017) (2)
Understanding Ethical, Legal and Societal Issues (ELSIs) in Human Biobanking and Genomics for Research and Healthcare in Zimbabwe: The Genomics Inheritance Law Ethics and Society GILES initiative. (2019) (2)
Opsoclonus-myoclonus associated with traditional medicine ingestion: case report. (1998) (2)
Measuring and Valuing Informal Care for Economic Evaluation of HIV/AIDS Interventions: Methods and Application in Malawi. (2016) (2)
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial (2022) (2)
Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation. (2017) (1)
In ﬂ ammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults (2016) (1)
Prevalence and risk of residual viremia after ART in low- and middle-income countries (2021) (1)
Mortality in patients with HIV-related tuberculous pericarditis (TBP) treated with adjunctive prednisolone (1998) (1)
Fatal myocarditis and pulmonary oedema following scorpion sting: report of two cases (1995) (1)
Immune restoration over 5 years on ART among patients initiating treatment with advanced immune deficiency in the DART trial in Uganda and Zimbabwe. (2010) (1)
Non-condom use among female nurses in Zambia. (1996) (1)
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min (2019) (1)
District-level strategies to control the HIV epidemic in Zimbabwe: a practical example of precision public health (2020) (1)
Task-sharing with lay counsellors to deliver a stepped care intervention to improve depression, antiretroviral therapy adherence and viral suppression in people living with HIV: a study protocol for the TENDAI randomised controlled trial (2022) (1)
Track C Epidemiology and Prevention Science (2012) (1)
Understanding Ethical, Legal and Societal Issues (ELSIs) in Human Biobanking and Genomics for Research and Healthcare in Zimbabwe: The Genomics Inheritance Law Ethics and Society (GILES) initiative (2019) (1)
The impact of meningitis on the motor function of adult survivors in Harare, Zimbabwe (1999) (1)
Annular subvalvular left ventricular aneurysm: A case report (1997) (1)
New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings. (2021) (1)
Editorial: HIV infection and the way forward for South Sudan (2014) (1)
Clinically relevant enantiomer specific R‐ and S‐praziquantel pharmacokinetic drug‐drug interactions with efavirenz and ritonavir (2021) (0)
Impact of sub-optimal HIV viral control on activated T-cells: an earnest sub study. (2023) (0)
Evidence for Action on HIV treatment and care systems in low and middle-income countries: background and introduction (2012) (0)
Endomyocardial fibrosis in children in Zimbabwe (1997) (0)
Neurocognitive function in patients failing first-line ART in Africa and responses to second-line (2015) (0)
Supporting Survivors of Stroke in Low Resource Settings (2019) (0)
Alternative Language Abstract S2 (2012) (0)
Reply to Boulware, Grant et al, and Bicanic et al (2010) (0)
Review NeuroAIDS in Afr ica (2010) (0)
Lack of minority K65R resistant viral populations detected after repeated interruptions of tenofovir DF/ zidovudine/lamivudine. (2009) (0)
Impact of a lopinavir/ritonavir (Kaletra) based second-line antiretroviral therapy regimen on lipid and lipoprotein profiles in an African setting. (2008) (0)
District-level differentiated HIV testing strategies are needed to achieve the 1st 90 in Zimbabwe (2020) (0)
What can be done about effusive tuberculous pericarditis in HIV-seropositive patients? (2007) (0)
O132 Secondline ART in the developing world (2008) (0)
Supporting Information S1 (2010) (0)
CRP and CD 4 + t-cell immune activation associated with HIV clinical progression in a multinational case-cohort study (2015) (0)
Risk of WHO 4 events and death by current CD4 on ART in the DART trial: the impact of CD4-dependent reporting bias. (2010) (0)
Insulin-like Growth Factor is Associated with Changes in Body Composition with ART Initiation (2017) (0)
Patient and programmatic characteristics, retention and predictors of attrition among patients starting antiretroviral therapy (ART) before and after the implementation of HIV “Treat All” in Zimbabwe (2020) (0)
Potent HBV therapy and availability of laboratory monitoring fail to abrogate increased risk of death in HBV-HIV-co-infected individuals in the DART study (2011) (0)
ART achievements and challenges in Africa (2010) (0)
Effect of WHO stage 3/4 events after ART initiation on survival of HIV-infected African adults in the DART trial. (2009) (0)
Most HIV-infected individuals on antiretroviral therapy ( ART ) in low and middle-income countries are treated following the World Health (2014) (0)
Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa (2017) (0)
Fine needle aspiration cytology in the diagnosis of hepatocellular carcinoma. (1995) (0)
Shifting ART Service provision: Health care workers' experience and challenges in Malawi and Zimbabwe. (2012) (0)
Effect of PI resistance mutations on viral load in patients on PI monotherapy (2016) (0)
A11 Evaluation of phylogenetic inference methods to determine direction of HIV transmission (2019) (0)
Diabetic Ketdacidosis At The Kenyatta National Hospital.a Prospective Study:1981-1982."presentation,precipitating Factors.mortality And Problems Of Management" (1983) (0)
The magnitude of loss to follow-up of HIV-exposed infants along the PMTCT continnm of care: a systematic literature review and meta-analysis. (2013) (0)
Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status. (2020) (0)
Track B Clinical Science (2012) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
TUPDC0103: Gonorrhea infections diagnosed among persons living with HIV: cross matching surveillance registries to identify potential opportunities for integrated partner services-New York City, Washington D.C., Miami/Dade County and Arizona (2012) (0)
Valvular heart disease in end-stage renal failure patients on maintenance haemodialysis (1995) (0)
Early mortality following ART initiation in HIV-infected adults and children in Uganda and Zimbabwe (2010) (0)
Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of e V usive tuberculous pericarditis in HIV seropositive patients (2000) (0)
Shifting Human Resources for Health in the context of ART provision in primary care facilities: qualitative and quantitative findings from the Lablite Baseline Survey (2013) (0)
Differential HIV risk factors among female general nurses. Nurse midwives and office workers/teachers in Zambia (1996) (0)
Causes and timing of mortality and morbidity among late presenters starting ART in the REALITY trial (2018) (0)
The Development of Anti-Retroviral Therapy in Africa (DART) trial. What have we learnt? (2009) (0)
Evaluation of a Training Intervention to Improve Kaposi Sarcoma Care in Zimbabwe: A Prospective Community-Based Stepped-Wedge Cluster Randomised Trial (2021) (0)
Lablite: Training needs for roll out of ART in Uganda and Zimbabwe using optimisation of clinical skills and minimisation of routine laboratory monitoring (2013) (0)
Low risk of alanine aminotransferase (ALT) flares in HBV/HIV coinfected patients starting HAART in the DART Study (2011) (0)
Impact of daily cotrimoxazole prophylaxis in severely immunosuppressed adults in Africa started on combination ART in the DART trial. (2009) (0)

This paper list is powered by the following services:

Other Resources About James Gita Hakim

en.wikipedia.org

What Schools Are Affiliated With James Gita Hakim?

James Gita Hakim is affiliated with the following schools: